WHO Just Changed How Obesity After 40 Is Treated. скачать в хорошем качестве

WHO Just Changed How Obesity After 40 Is Treated.

WHO just changed the obesity conversation — and for adults over 40, this may be far bigger than most people realize. In this video, we break down what the World Health Organization’s new GLP-1 obesity guidance actually means, what these medications really do, what they do not do, and why obesity after 40 is increasingly being treated as a chronic, complex, relapsing disease rather than a simple willpower problem. We also cover why this matters more in midlife and beyond: insulin resistance, poor sleep, sleep apnea, fatty liver, rising blood pressure, menopause-related body composition changes, lower muscle mass, and the feeling that your body is no longer responding the way it used to. Most importantly, we talk about the trade-offs people need to hear clearly — side effects, weight regain after stopping treatment, long-term planning, and why preserving strength, protein intake, muscle mass, and real health matters more than just seeing a lower number on the scale. If you’ve ever wondered whether weight after 40 is really just about discipline, this video gives you a more honest, evidence-aware answer. Sources: World Health Organization — GLP-1 guideline for obesity: [https://www.who.int/news/item/01-12-2...](https://www.who.int/news/item/01-12-2...) World Health Organization — Obesity and overweight: [https://www.who.int/news-room/fact-sh...](https://www.who.int/news-room/fact-sh...) World Health Organization — GLP-1 therapies Q&A: [https://www.who.int/news-room/questio...](https://www.who.int/news-room/questio...) NIDDK / NIH — Health risks of overweight and obesity: [https://www.niddk.nih.gov/health-info...](https://www.niddk.nih.gov/health-info...) NIDDK / NIH — Weight management: [https://www.niddk.nih.gov/health-info...](https://www.niddk.nih.gov/health-info...) PubMed — Changes in lean body mass with GLP-1-based therapies: [https://pubmed.ncbi.nlm.nih.gov/38937...](https://pubmed.ncbi.nlm.nih.gov/38937...) PubMed — Effect of GLP-1 receptor agonists on body composition: [https://pubmed.ncbi.nlm.nih.gov/39719...](https://pubmed.ncbi.nlm.nih.gov/39719...) PubMed — Mitigating loss of lean muscle in GLP-1 and dual agonist therapy: [https://pubmed.ncbi.nlm.nih.gov/41587...](https://pubmed.ncbi.nlm.nih.gov/41587...) Disclaimer: This video is for educational purposes only and is not medical advice, diagnosis, or treatment. Decisions about obesity treatment, including GLP-1 therapy, should be made with a licensed healthcare professional who can evaluate your medical history, risks, goals, side effects, and alternatives. #GLP1 #ObesityAfter40 #WeightLossAfter40 #MetabolicHealth #HealthyAging #ObesityTreatment #MidlifeHealth #InsulinResistance #MenopauseWeightGain #SleepApnea #FattyLiver #MuscleHealth #ChronicDisease #BloodPressure #HealthOver40